SEC 13F Intelligence

Managers / Q2 2020 · view latest →

Boxer Capital, LLC

CIK 0001465837 · 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130 · (858) 400-3112

Reported Value
$2.3B
Q2 2020
Positions
65
Filings on Record
27
2019–present window
Filed
Aug 14, 2020
original filing

Summary

Boxer Capital, LLC reported $2.3B in U.S.-listed holdings across 65 positions for Q2 2020.

Its largest position, IMMU, represents 10.3% of the portfolio.

Compared with Q1 2020, the fund opened 7 new positions and exited 4.

Portfolio Metrics

Turnover
+5.2%
vs prior filed quarter
Top-10 Concentration
+52.3%
share of reported value
Largest Position
+10.3%
Immunomedics
New / Exited
7 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $809MQ4 ’18Q1 ’19: $865MQ2 ’19: $1.2BQ3 ’19: $1.4BQ3 ’19Q4 ’19: $1.8BQ1 ’20: $1.5BQ2 ’20: $2.3BQ2 ’20Q3 ’20: $2.9BQ4 ’20: $3.1BQ1 ’21: $2.9BQ1 ’21Q2 ’21: $2.8BQ3 ’21: $2.9BQ4 ’21: $2.6BQ4 ’21Q1 ’22: $1.9BQ2 ’22: $1.6BQ3 ’22: $1.8BQ3 ’22Q4 ’22: $1.9BQ2 ’23: $2MQ4 ’23: $2.0BQ4 ’23Q1 ’24: $2.0BQ2 ’24: $1.9BQ3 ’24: $2.0BQ3 ’24Q4 ’24: $0filingsflow.com

Portfolio Composition

By security type
Common Stock: 71.7%Other: 17.3%ADR: 9.9%ETP: 1.1%
  • Common Stock · 71.7% · $1.6B
  • Other · 17.3% · $394M
  • ADR · 9.9% · $225M
  • ETP · 1.1% · $24M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PRNBPRINCIPIA BIOPHARMA INCNEW+607.0K607.0K+$36M$36M
RNAGBPAVIDITY BIOSCIENCES INCNEW+1.12M1.12M+$32M$32M
TCE2CELLDEX THERAPEUTICS INC NEWNEW+1.00M1.00M+$13M$13M
FULCFULCRUM THERAPEUTICS INCNEW+705.9K705.9K+$13M$13M
ICPTUSDINTERCEPT PHARMACEUTICALS INNEW+126.0K126.0K+$6M$6M
IOVAIOVANCE BIOTHERAPEUTICS INCNEW+200.0K200.0K+$5M$5M
AGLEUSDAEGLEA BIOTHERAPEUTICS INCNEW+550.0K550.0K+$5M$5M
ZYMEUSDZYMEWORKS INCADDED+140.0K165.0K+$5M$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1IMMUIMMUNOMEDICS INChistory →COM10.29%$234M6.61M
2MRTXEURMIRATI THERAPEUTICS INChistory →COM8.86%$202M1.77M
3ONCBEIGENE LTDhistory →SPONSORED ADR7.66%$174M925.0K
4ODONATE THERAPEUTICS INCCOM6.26%$142M3.36M
5RVMDREVOLUTION MEDICINES INChistory →COM4.11%$93M2.96M
6SWTXUSDSPRINGWORKS THERAPEUTICS INChistory →COM3.83%$87M2.08M
7BDTXBLACK DIAMOND THERAPEUTICS Ihistory →COM3.73%$85M2.01M
8SGENUSDSEATTLE GENETICS INChistory →COM2.99%$68M400.0K
9PASSAGE BIO INCCOM2.32%$53M1.93M
10RCUSARCUS BIOSCIENCES INChistory →COM2.27%$52M2.08M
11ESPRESPERION THERAPEUTICS INC NEhistory →COM2.20%$50M975.0K
12ALLKGUSDALLAKOS INChistory →COM2.13%$49M675.0K
13AMARIN CORP PLCSPONS ADR NEW2.13%$48M7.00M
14SG7SAGE THERAPEUTICS INChistory →COM2.00%$45M1.09M
15ARGXARGENX SEhistory →SPONSORED ADR1.69%$38M170.9K
16ATRECA INCCL A COM1.62%$37M1.73M
17PRNBPRINCIPIA BIOPHARMA INChistory →COM1.60%$36M607.0K
18COMPUGEN LTDORD1.57%$36M2.38M
19AM6AMICUS THERAPEUTICS INChistory →COM1.54%$35M2.33M
20UNIQURE NVSHS1.52%$34M765.4K
21SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.49%$34M2.29M
22GOSSGOSSAMER BIO INChistory →COM1.46%$33M2.56M
23TREURTRILLIUM THERAPEUTICS INChistory →COM NEW1.45%$33M4.08M
24KDMNKADMON HLDGS INChistory →COM1.40%$32M6.21M
25RNAGBPAVIDITY BIOSCIENCES INChistory →COM1.39%$32M1.12M
26IDYAIDEAYA BIOSCIENCES INChistory →COM1.38%$31M2.20M
27DBV TECHNOLOGIES S ASPONSORED ADR1.36%$31M7.03M
28BMRNBIOMARIN PHARMACEUTICAL INChistory →COM1.36%$31M250.0K
29RCKTROCKET PHARMACEUTICALS INChistory →COM1.35%$31M1.47M
30ANABANAPTYSBIO INChistory →COM1.28%$29M1.30M
31MRNSUSDMARINUS PHARMACEUTICALS INChistory →COM1.07%$24M9.60M
32DIREXION SHS ETF TRDAILY S&P BIOTEC1.07%$24M7.00M
33BLUBELLUS HEALTH INC NEWhistory →COM NEW0.80%$18M1.77M
34ACADACADIA PHARMACEUTICALS INChistory →COM0.79%$18M370.0K
35CABACABALETTA BIO INChistory →COM0.77%$17M1.57M
36NEOLEUKIN THERAPEUTICS INCCOM0.74%$17M1.01M
37PREVAIL THERAPEUTICS INCCOM0.74%$17M1.12M
38GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM0.69%$16M250.0K
39AGENEURAGENUS INChistory →COM NEW0.69%$16M4.00M
40KURAKURA ONCOLOGY INChistory →COM0.61%$14M844.8K
41RLMDRELMADA THERAPEUTICS INChistory →COM0.59%$13M300.0K
42TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW0.57%$13M1.00M
43FULCFULCRUM THERAPEUTICS INChistory →COM0.57%$13M705.9K
44MREOMEREO BIOPHARMA GROUP PLChistory →ADS0.54%$12M4.03M
45MEI PHARMA INCCOM NEW0.53%$12M2.91M
46AKROAKERO THERAPEUTICS INChistory →COM0.46%$10M416.5K
47KODKODIAK SCIENCES INCCOM0.43%$10M181.1K
48SELECTA BIOSCIENCES INCCOM0.41%$9M3.28M
49MTNBEURMATINAS BIOPHARMA HLDGS INCCOM0.39%$9M11.48M
50XENEXENON PHARMACEUTICALS INCCOM0.33%$8M600.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2024$01Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B68Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$1.9B61Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$2.0B59May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.0B52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023Under review73Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2M79Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023Under review75May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$1.9B71Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$1.8B73Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$1.6B76Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$1.9B74May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$2.6B71Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$2.9B88Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$2.8B95Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$2.9B85May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B78Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.9B75Nov 17, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$2.3B65Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$1.5B62May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.8B51Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$1.4B49Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019REVEALED$1.2B37Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$865M23May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$809M24Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.